ライフサイエンスコーパス: renal dysfunction

1 ease (such as thrombocytopenia or hepatic or renal dysfunction).

2 iring cardiopulmonary bypass, no preexisting renal dysfunction.

3 partially contribute to TFV and ADV induced renal dysfunction.

4 eloped hypophosphatemic rickets secondary to renal dysfunction.

5 composite of death, dialysis, or persistent renal dysfunction.

6 iabetes mellitus, myocardial infarction, and renal dysfunction.

7 gher hs-cTnI concentrations and any level of renal dysfunction.

8 slipidemia, atrial fibrillation, anemia, and renal dysfunction.

9 ion, mechanical circulatory support and with renal dysfunction.

10 3-deficient rats develop podocyte injury and renal dysfunction.

11 se disorders in patients without significant renal dysfunction.

12 , hypotension, electrolyte disturbances, and renal dysfunction.

13 y at discharge, anemia, current smoking, and renal dysfunction.

14 nstrated to be effective in mild to moderate renal dysfunction.

15 le of dairy consumption in the prevention of renal dysfunction.

16 ion (FDA) use different criteria to classify renal dysfunction.

17 F enrolled AHF patients (n=360; any EF) with renal dysfunction.

18 reserved renal function in AHF patients with renal dysfunction.

19 ominantly afflicts individuals with advanced renal dysfunction.

20 asma soluble fms-like tyrosine kinase 1, and renal dysfunction.

21 populations, such as women and patients with renal dysfunction.

22 coronary bypass grafting, heart failure, and renal dysfunction.

23 idney allocation to 70% of our patients with renal dysfunction.

24 ciencies, bilateral congenital cataracts and renal dysfunction.

25 n and cause end-organ dysfunction, including renal dysfunction.

26 4rKO mice, leads to heightened BP and severe renal dysfunction.

27 lin light chains in the kidney, resulting in renal dysfunction.

28 alt-sensitive hypertension solely to primary renal dysfunction.

29 in high diagnostic accuracy in patients with renal dysfunction.

30 t in those without TG despite other forms of renal dysfunction.

31 on in death and HF among those with moderate renal dysfunction.

32 sis patients, who are uniquely vulnerable to renal dysfunction.

33 tain their clinical utility in patients with renal dysfunction.

34 olerated despite advanced liver and moderate renal dysfunction.

35 final diagnosis in 36% of all patients with renal dysfunction.

36 function at 1 year in patients with baseline renal dysfunction.

37 ing in patients with ADPKD in the absence of renal dysfunction.

38 increase the mortality rate in patients with renal dysfunction.

39 proves eGFR and proteinuria in patients with renal dysfunction.

40 e being used in patients with some degree of renal dysfunction.

41 ergoing inpatient angiography with worsening renal dysfunction.

42 specifically excluded patients with (severe) renal dysfunction.

43 ein deacetylation and degradation as well as renal dysfunction.

44 represent a therapeutic strategy to prevent renal dysfunction.

45 indication for belatacept was perioperative renal dysfunction.

46 lected liver transplant (LT) candidates with renal dysfunction.

47 e of increased cardiac filling pressures and renal dysfunction.

48 d with less bleeding across the continuum of renal dysfunction.

49 2) scores 4 to 6, and patients with moderate renal dysfunction.

50 ents may have proteinuria, hematuria, and/or renal dysfunction.

51 f CKD prevents fibrosis and protects against renal dysfunction.

52 h acute kidney injury and "acute on chronic" renal dysfunction.

53 arance of the glucuronide metabolites with a renal dysfunction.

54 ociated with heart failure (HF) severity and renal dysfunction.

55 ver disease is suboptimal in the presence of renal dysfunction.

56 rapy even with moderate or moderately severe renal dysfunction.

57 e without altering hypertension or degree of renal dysfunction.

58 n vascular patients with or without moderate renal dysfunction.

59 de bioavailability, causing hypertension and renal dysfunction.

60 , elevated systolic blood pressure (SBP) and renal dysfunction.

61 between miR-103a-3p levels and AngII-induced renal dysfunction.

62 omarkers associated with the pathogenesis of renal dysfunction.

63 rophy/dysfunction, vascular dysfunction, and renal dysfunction.

64 d-brain barrier permeability associated with renal dysfunction.

65 or prognosis, especially in individuals with renal dysfunction.

66 d renal fibrosis, whereas it did not lead to renal dysfunction.

67 laxin reversed DOCA-salt induced cardiac and renal dysfunction.

68 r hemolysis and plasma hemoglobin-associated renal dysfunction.

69 nd further enhance vascular inflammation and renal dysfunction.

70 up developed rash (13.9% vs 4.2%; P = .002), renal dysfunction (11.4% vs 3.3%; P = .006), and liver f

71 %), skin scarring (5.4%), amputation (3.4%), renal dysfunction (2.6%), and seizures (2.5%).

72 f etiology, severity, duration, and level of renal dysfunction; (2) documentation of degree of nonrev

73 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI, CAI, and time with oxygen s

74 gan dysfunction syndrome (34%), shock (28%), renal dysfunction (25%), and acute respiratory distress

75 eglitazar vs 1.7% for placebo, P = .03), and renal dysfunction (7.4% for aleglitazar vs 2.7% for plac

76 82.0%), diabetes (44.8% vs 34.6%), advanced renal dysfunction (8.7% vs 2.3%), prior myocardial infar

77 e tubulointerstitial fibrosis, inflammation, renal dysfunction, activation of NF-kappaB, TGF-beta, an

78 Left ventricular size, renal dysfunction, advanced age, and atrial fibrillation

79 re, we strive to explore whether the type of renal dysfunction affects estimated glomerular filtratio

80 t with NAC and NaHCO3 may reduce the risk of renal dysfunction after 30 days.

81 Renal dysfunction after congenital renal mass reduction

82 s shown that DGF, encompassing a spectrum of renal dysfunction after kidney transplantation including

83 tinine (SCr) would be useful to detect early renal dysfunction after transplantation.

84 >1 prior MI, multivessel disease, diabetes, renal dysfunction (all with ICERs $50,000 to $70,000/QAL

85 onship between both severity and recovery of renal dysfunction and 90-day mortality after major surge

86 e adjustment of the agents in the setting of renal dysfunction and avoidance of the concomitant use o

87 preexisting coronary artery disease reduced renal dysfunction and cardiac injury, potentially result

88 cessive multisystem disorder Arthrogryposis, Renal dysfunction and Cholestasis syndrome caused by VIP

89 sly reported in patients with arthrogryposis renal dysfunction and cholestasis syndrome.

90 n-glyphosate herbicides was likely to induce renal dysfunction and decrease of serum folic acid.

91 ontinuous renal replacement therapy for both renal dysfunction and detoxification.

92 Renal dysfunction and dialysis reduced the rule-in perfo

93 Among patients with renal dysfunction and elevated baseline cTn levels (>/=9

94 This association was independent of renal dysfunction and female gender, both of which were

95 vation at a late-stage of CKD abrogated both renal dysfunction and fibrosis, which was associated wit

96 th a late B lymphocyte signature relating to renal dysfunction and fibrosis.

97 Liver transplant candidates with advanced renal dysfunction and HCC may be considered for SLK.

98 e yet to be fully evaluated in patients with renal dysfunction and in the transplant population.

99 ential cause of hypertension and progressive renal dysfunction and its clinical and research implicat

100 urinalysis indicate that Hpse2 mutants have renal dysfunction and malnutrition.

101 Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhi

102 s of stay, and higher rates of postoperative renal dysfunction and MI.

103 n appeared to be associated with lower early-renal dysfunction and no additional risk of hepatic dysf

104 distal to renal artery stenosis is linked to renal dysfunction and poor outcomes.

105 hibition of PTEN with bpV(HOpic) exacerbated renal dysfunction and promoted tubular damage in mice wi

106 podKO) mice or cells with 2,4-diHB prevented renal dysfunction and reversed podocyte migration rate i

107 ith V. vulnificus by alleviating hepatic and renal dysfunction and systemic inflammation.

108 ailure and the interactions between baseline renal dysfunction and the effect of randomized treatment

109 Our data illustrate the frequency of renal dysfunction and the powerful prognostic value of l

110 antagonist BR-4628 can prevent or treat the renal dysfunction and tubular injury induced by IR.

111 ytic functions of the endothelium, prevented renal dysfunction, and attenuated nephrosclerosis.

112 Arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome is cau

113 patients with heart failure with or without renal dysfunction, and compare it with 2 frequently used

114 prior revascularization, diabetes mellitus, renal dysfunction, and current smoking.

115 ties, such as atherosclerosis, hypertension, renal dysfunction, and diabetes mellitus; as a result, t

116 ular collagen deposition, aortic stiffening, renal dysfunction, and hypertension with age.

117 ed vascular inflammation, aortic stiffening, renal dysfunction, and hypertension; however, adoptive t

118 according to age, sepsis severity, degree of renal dysfunction, and immunocompetence are warranted.

119 conditions involving systemic inflammation, renal dysfunction, and increased adiposity.

120 i-INT was associated with histological ATN, renal dysfunction, and increased incident fibrosis on se

121 ere associated with inflammatory biomarkers, renal dysfunction, and long-term cardiovascular mortalit

122 97) had higher pretest clinical scores, more renal dysfunction, and lower left ventricular ejection f

123 suboptimal, in terms of virologic clearance, renal dysfunction, and mortality.

124 However, off-target electrolyte wasting, renal dysfunction, and neurohormonal activation were not

125 topenia, anasarca, fever, reticulin fibrosis/renal dysfunction, and organomegaly.

126 disease, recent acute myocardial infarction, renal dysfunction, and patient >=70 years of age.

127 lial function, greater liver stiffness, more renal dysfunction, and poorer exercise capacity.

128 ate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop pr

129 C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an

130 or bleeding were more frequent in those with renal dysfunction, and the frequency of these outcome ev

131 Patients with AF have a higher incidence of renal dysfunction, and the latter predisposes to inciden

132 D-Dimer cutoff levels adjusted for renal dysfunction appear feasible and safe assessing thr

133 Liver fibrosis and renal dysfunction are common and may progress over time.

134 The DMF cotreatment ameliorated CsA-induced renal dysfunction as evidenced by significant decrease i

135 -sensitive hypertension is not due solely to renal dysfunction, as predicted by the G-C model, but ma

136 cidemia was only observed in the presence of renal dysfunction, as rapidly detected by alactic base e

137 The proportion with moderate or severe renal dysfunction at baseline was lower in the TDF than

138 Among patients with moderate or severe renal dysfunction at baseline, renal function improved i

139 For patients with renal dysfunction at listing for LT, not listed for simu

140 ccess and survival of SLKT for patients with renal dysfunction at listing for LT.

141 up to half of patients with MM present with renal dysfunction at the time of diagnosis.

142 , blood pressure, lung function, heart rate, renal dysfunction, atrial fibrillation, forced expirator

143 f choice in renal-transplant recipients with renal dysfunction attributed to calcineurin inhibitor (C

144 For older patients and for patients with renal dysfunction, bendamustine and rituximab may be a b

145 rrest, pulmonary edema on chest x-ray, acute renal dysfunction, bleeding requiring transfusion or int

146 e responsible for tubular cell apoptosis and renal dysfunction but can be restored using ad-MSC.

147 levels, the levels of cardiac biomarkers, or renal dysfunction but correlated with low systolic blood

148 ited diabetic glomerulosclerosis and reduced renal dysfunction but had no effect on the development o

149 Patients with mild renal dysfunction by FDA criteria have routinely been en

150 tients enrolled onto phase I trials had mild renal dysfunction by FDA criteria.

151 who fulfill criteria for nonreversibility of renal dysfunction (by level and duration of renal dysfun

152 atus; and the presence of diabetes mellitus, renal dysfunction, cardiac arrest, cardiogenic shock, an

153 re associated with an increased incidence of renal dysfunction, cardiovascular complications, and de

154 (acetate, propionate, and butyrate) improved renal dysfunction caused by injury.

155 Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome-associated

156 Despite equivalent BP and renal dysfunction, CKDu subjects had a lower PWV than th

157 mong 2813 unselected patients, 447 (16%) had renal dysfunction (defined as Modification of Diet in Re

158 Patients with acute heart failure and renal dysfunction demonstrate variable rise and fall in

159 eedom from coronary angioplasty or stenting, renal dysfunction, diabetes mellitus, CMV infection, or

160 In patients with renal dysfunction, diagnostic accuracy at presentation,

161 e of major adverse kidney events (persistent renal dysfunction, dialysis dependence, and mortality) a

162 esolves, and whether patterns of reversal of renal dysfunction differ among patients with respect to

163 Renal dysfunction, diuretic resistance, and hyponatremia

164 The AMR was defined as 3 of 4 criteria: renal dysfunction, donor specific antibody, C4d positivi

165 of IRAK-M did not affect immunopathology and renal dysfunction during early postischemic AKI.

166 there were insufficient patients with severe renal dysfunction (eGFR <30 ml/min/1.73 m(2)) to draw co

167 n 1962 patients with acute heart failure and renal dysfunction enrolled in the Placebo-Controlled Ran

168 alized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate

169 pertension, diabetes, dyslipidemia, obesity, renal dysfunction, etc.) be treated in the candidate for

170 from metabolic disturbances despite similar renal dysfunction following adenine experimental uremia.

171 n, the remaining 6 patients with uveitis and renal dysfunction fulfilled the criteria of probable TIN

172 es severity and in presence of a significant renal dysfunction (GFR <60 mL/min/1.73 m(2)).

173 n the kidneys of patients with cirrhosis and renal dysfunction has prompted the functional nature of

174 ELD) prioritization of liver recipients with renal dysfunction has significantly increased utilizatio

175 d isolated advanced age, low body weight, or renal dysfunction have a higher risk of stroke or system

176 any traditional risk factors associated with renal dysfunction have been linked with cognitive declin

177 The severity and duration of pretransplant renal dysfunction, hepatitis c, diabetes, and other risk

178 orticosteroids, higher perceived cardiac and renal dysfunction, higher perceived posttransplantation

179 urvival for liver transplant recipients with renal dysfunction; however, the tenuous perioperative he

180 urvival for liver transplant recipients with renal dysfunction; however, the tenuous perioperative he

181 nd 0, 1, 2, or >/=3 comorbidities, including renal dysfunction, hypertension (HTN), diabetes, coronar

182 In 5 studies that included data on renal dysfunction, ICD implantation was associated with

183 e the first choice in patients with moderate renal dysfunction if they have the appropriate anatomy.

184 renal dysfunction (by level and duration of renal dysfunction, imaging, and pathology findings), wou

185 RAAS inhibitors induce renal dysfunction in both HFREF and HFPEF.

186 ation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although further validat

187 n T2D-PTECs that may contribute to sustained renal dysfunction in DKD.

188 eatment with serelaxin prevented cardiac and renal dysfunction in DOCA-salt rats.

189 ive heart disease but also with the level of renal dysfunction in HFrEF.

190 Perioperative renal dysfunction in liver transplant recipients complic

191 d male gender are associated with subsequent renal dysfunction in low-risk pediatric patients, especi

192 hat reduced CI is not the primary driver for renal dysfunction in patients hospitalized for HF, irres

193 nts an underestimated but important cause of renal dysfunction in patients with cholestasis and advan

194 could ameliorate renal vasoconstriction and renal dysfunction in patients with cirrhosis and portal

195 c index (CI) is a significant contributor to renal dysfunction in patients with heart failure (HF).

196 umarate (tenofovir) has been associated with renal dysfunction in people infected with human immunode

197 usses a number of features and mechanisms of renal dysfunction in pulmonary disorders in relation to

198 d restore the microcirculation and alleviate renal dysfunction in renovascular disease.

199 The mechanistic basis for cardiac and renal dysfunction in sepsis is unknown.

200 zed mechanism underlying the pathogenesis of renal dysfunction in type 1 diabetes.

201 were older and had more chronic illness and renal dysfunction; in the gamma phenotype (n = 5385; 27%

202 Over time, however, Cul3 deletion caused renal dysfunction, including hypochloremic alkalosis, di

203 HS, and to determine whether the severity of renal dysfunction influenced the provision of angiograph

204 d according to the pediatric RIFLE (risk for renal dysfunction, injury to the kidney, failure of kidn

205 induced lipid accumulation in the kidney and renal dysfunction, injury, inflammation, and fibrosis.

206 In patients with heart failure, renal dysfunction is associated with a poor outcome.

207 In patients with mild HF, moderate renal dysfunction is associated with higher risk of deat

208 Renal dysfunction is associated with lower survival in p

209 Renal dysfunction is frequent in liver cirrhosis and is

210 Renal dysfunction is intricately linked to aortic stenos

211 active renal vasculitis from other causes of renal dysfunction is lacking, with a kidney biopsy often

212 ischemia/reperfusion (I/R)-induced AKI, when renal dysfunction is maximal, would accelerate recovery

213 Outside hospital, renal dysfunction is more strongly associated with morta

214 ation; however, the long-term implication of renal dysfunction is not well established in this popula

215 However, renal dysfunction is often observed in patients with thr

216 portant clinical decisions depend on whether renal dysfunction is recoverable after LT.

217 in patients with more advanced cirrhosis and renal dysfunction is required.

218 We hypothesized that renal dysfunction is underpinned by a reduced contributi

219 to cardiac pathologies before development of renal dysfunction is unknown.

220 t of orthotopic liver transplantation (OLT), renal dysfunction is used as a criterion for simultaneou

221 t biopsy for the occurrence of dnDSA without renal dysfunction leads to the diagnosis of a sAMR in ov

222 tients without cardiovascular comorbidities, renal dysfunction, left ventricular dysfunction, or sign

223 Encephalopathy, hepatic, and renal dysfunction manifested later than cardiovascular a

224 These results suggest that severe renal dysfunction may be marginally reversible after LT,

225 different phenotypes of patients with acute renal dysfunction may be present, which has ramification

226 Depression and renal dysfunction may increase the risk of VAD infection

227 moderate, or refractory) and to hepatic and renal dysfunctions (MELD score </= or >15 and KDOQI stag

228 to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myoc

229 pecificity, 39.2%) and/or "acute on chronic" renal dysfunction (negative predictive value, 98.0%; sen

230 erminal probrain natriuretic peptide levels, renal dysfunction, neurohumoral activation, myocardial n

231 patient was not undergoing dialysis for her renal dysfunction, nor was she receiving steroids for CO

232 Renal dysfunction occurred in 20 (51%) of 39 by end of t

233 Renal dysfunction occurred in 461 (24.3%).

234 ger age group, apart from cardiovascular and renal dysfunction, older patients received less organ su

235 tive cohort of patients aged >=18 years with renal dysfunction on the liver transplant (LT) waiting l

236 odynamic factors, such as high uric acid and renal dysfunction, on changes in the left ventricular ma

237 oning (AKI OR 1.35, 0.76-2.39 and persistent renal dysfunction OR 1.05, 0.12-9.45).

238 I (OR 2.79, 95% CI 1.45-5.37) and persistent renal dysfunction (OR 3.82, 1.32-11.05) only in patients

239 1.94, 95% CI 1.08-3.47, p=0.026), persistent renal dysfunction (OR 6.67, 1.67-26.61, p=0.0072), and d

240 ere patient age (OR, 1.17) and postoperative renal dysfunction (OR, 16.33).

241 95% CI: 0.31 to 0.76 per mg/dl of albumin), renal dysfunction (OR: 2.1, 95% CI: 1.4 to 3.2 per mg/dl

242 association between hemoglobin and brain or renal dysfunction, or ICU mortality.

243 rombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not

244 C-reactive protein, reticulin myelofibrosis, renal dysfunction, organomegaly (TAFRO) clinical subtype

245 tion correlated with both the development of renal dysfunction over the 72 hours after urine collecti

246 often with shock, pulmonary infiltrates, and renal dysfunction (p < 0.0001 for all comparisons).

247 d brain dysfunction (p = 0.69 for delirium), renal dysfunction (p = 0.30), or ICU mortality (p = 0.95

248 no evidence of potassium wasting (P=0.20) or renal dysfunction (P>0.11 for all biomarkers), whereas b

249 iated with development of ascites (P=0.057), renal dysfunction (P=0.004), bacterial infections (P=0.0

250 to be an attractive option for patients with renal dysfunction, peripheral arterial disease, or follo

251 line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other com

252 versus 51.4+/-11.8 years; P<0.001), had more renal dysfunction, prior cancer, and smoking.

253 CXCL16 knockout mice exhibited less severe renal dysfunction, proteinuria, and fibrosis after DOCA-

254 who had pre-LT kidney biopsy for unexplained renal dysfunction, proteinuria, and hematuria were retro

255 and had a higher prevalence of hypertension, renal dysfunction, pulmonary disease, and vascular disea

256 Because patients with renal dysfunction (RD) frequently present with increased

257 Identifying reversible renal dysfunction (RD) in the setting of heart failure i

258 lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF

259 ients had lower rates of DGF (5% vs 20%) and renal dysfunction-related readmissions (10% vs 27.5%) (P

260 However, predicting which donors will have renal dysfunction remains challenging, particularly amon

261 as been documented in patients with CHD with renal dysfunction, restrictive lung disease, anemia, and

262 OPEN in patients with moderate renal dysfunction resulted in significantly higher morta

263 Renal dysfunction reversibility was evaluated at day 3.

264 Cystatin C (CysC) is an early biomarker of renal dysfunction scarcely studied in patients awaiting

265 has significantly increased the incidence of renal dysfunction seen among patients undergoing liver t

266 ff levels, which are higher in patients with renal dysfunction, should be considered.

267 r age, vascular surgery, bleeding event, and renal dysfunction strongly predict long-term mortality a

268 Old mice developed marked hepatic and/or renal dysfunction, supported by elevations in plasma asp

269 crystalloids result in less death or severe renal dysfunction than saline.

270 gnosed by a pediatric nephrologist as having renal dysfunction that suggested acute interstitial neph

271 as cardiomyopathy, retinal degeneration and renal dysfunction, the disorder is characterized by high

272 After excluding other causes of renal dysfunction, the remaining 6 patients with uveitis

273 than 1 year after LT alone (n = 8) developed renal dysfunction thereafter.

274 Among patients with no or mild renal dysfunction, those receiving TDF were more likely

275 y associated with hepatobiliary dysfunction, renal dysfunction, thrombocytopenia, and hyperlactatemia

276 effects on renal fibrosis and the resultant renal dysfunction, thus it could represent a therapeutic

277 AKI mouse model, in which gallein attenuated renal dysfunction, tissue damage, fibrosis, inflammation

278 such as ultrafiltration, may also result in renal dysfunction to a greater extent than medical thera

279 ple diagnostic screening tools for detecting renal dysfunction to diagnose TINU syndrome in young pat

280 ly invasive approach in patients with severe renal dysfunction to ensure that all patients who may be

281 motherapy, even among patients with advanced renal dysfunction, to delay progression to ESRD and prev

282 In future oncology renal dysfunction trials based on the FDA classification

283 of stage III (moderate) or stage IV (severe) renal dysfunction was 72%, 64%, and 75% for treatment wi

284 Relative to normal function, mild renal dysfunction was associated with a statistically si

285 Renal dysfunction was associated with increased CV risk

286 Renal dysfunction was categorized as mild (estimated glo

287 Renal dysfunction was defined as estimated glomerular fi

288 Baseline renal dysfunction was more prevalent in older patients w

289 Progressive renal dysfunction was noted among patients with C-TCMR a

290 Renal dysfunction was observed in 1,364 (9.4%) of the to

291 erator characteristic curve in patients with renal dysfunction was only slightly lower than in patien

292 After IRI, renal dysfunction was prolonged after the high-dose gall

293 intrarenal inflammation, tubular damage, and renal dysfunction were abrogated in mice deficient in My

294 interval, 3.95-8.15) and measures of hepatic/renal dysfunction were inversely associated with the rec

295 abetes mellitus, higher body mass index, and renal dysfunction were more common among those with LVDD

296 e-derived cTn cutoff levels in patients with renal dysfunction were significantly higher compared wit

297 long-term benefit over SAR in patients with renal dysfunction who require CABG.

298 more severe HF, with glomerular and tubular renal dysfunction, with incidence of a deterioration of

299 one, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard o

300 urvival benefit in patients with and without renal dysfunction, yet renal impairment is an important